The COMPASS trial: practical considerations for application after coronary artery bypass surgery

Area of Science:

• Cardiology
• Pharmacology
• Vascular Surgery

Background:

• Coronary artery bypass grafting (CABG) is a common procedure for coronary artery disease.
• Patients undergoing CABG are at high risk for atherothrombotic events.
• Optimizing anticoagulation strategies post-CABG is crucial for patient outcomes.

Purpose of the Study:

• To review the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.
• To emphasize outcomes in patients with a history of remote CABG or enrolled 4-14 days post-CABG.
• To provide guidance on patient selection for anticoagulation therapy post-CABG, balancing benefits and bleeding risks.

Main Methods:

• Review of the COMPASS trial data.
• Analysis of subgroups including patients with prior or recent CABG.
• Discussion of bleeding risk and comparison of anticoagulation regimens.

Main Results:

• Rivaroxaban plus aspirin demonstrated a reduction in myocardial infarction, stroke, and cardiovascular death in patients with coronary artery disease.
• No significant effect on bypass graft patency was observed in the first postoperative year.
• The COMPASS regimen was associated with increased bleeding risk, necessitating careful patient selection.

Conclusions:

• Cardiac surgeons should consider the COMPASS regimen (rivaroxaban and aspirin) for high-risk thrombosis patients post-CABG with acceptable bleeding risk.
• The regimen should be continued indefinitely to prevent long-term atherothrombotic events.
• This strategy complements other pharmacological risk reduction therapies.